SEM can be used to examine barriers associated with enrollment in clinical studies and lead to sustainable engagement in clinical studies.3 A novel approach to reduce inequities in APOL1-mediated kidney disease would be to adapt principles of the SEM to identify challenges and sustainable opportunities to advance diversity for APOL-1 clinical study participation to improve the generalizability of clinical study results. The gene discussed is APOL1; the disease is kidney disorder.